Charles River to close ‘15 smaller sites’ as demand for early research declines

In an­oth­er sign that bio­phar­ma com­pa­nies are slow­ing their ear­ly R&D ef­forts, Charles Riv­er Lab­o­ra­to­ries is shut­ter­ing more than a dozen sites.

The ser­vice provider …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.